Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
The new Zigly center features and offers comprehensive veterinary services
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
Subscribe To Our Newsletter & Stay Updated
